RetaMaps

VCU / Central Virginia VA Endocrinology — Stephanie B. Mayer, MD, MHSc

Hunter Holmes McGuire VA / VCU Endocrinology · 1201 Broad Rock Blvd, Dept. of Internal Medicine/Endocrinology · Richmond, VA 23249

3.8· 425 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

About this practice

VCU’s Division of Endocrinology, Diabetes and Metabolism is an academic program providing inpatient and outpatient care at VCU Medical Center and the Richmond VA Medical Center, with teaching, fellowship training, and research in diabetes, osteoporosis, PCOS, and obesity. Stephanie B. Mayer, MD, MHSc, is listed among VA Medical Center faculty; the Hunter Holmes McGuire VA location is 1201 Broad Rock Blvd. This is VA/academic endocrinology (eligibility-specific), not a cash GLP-1 clinic; official pages do not name GLP-1 brands.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visits—
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice website—

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 3.8
Google rating · 425 reviews
19
reviews in the past year (avg ★ 3.2)

Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-24. Read the reviews themselves on the practice's Google listing.

Clinicians

  • Stephanie B. Mayer, MD, MHSc

Nearby providers in Richmond

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs